<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antibiotic lock solution concentrations for adjunctive treatment of non-hemodialysis catheter-related bloodstream infection (CRBSI)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antibiotic lock solution concentrations for adjunctive treatment of non-hemodialysis catheter-related bloodstream infection (CRBSI)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antibiotic lock solution concentrations for adjunctive treatment of non-hemodialysis catheter-related bloodstream infection (CRBSI)</div><div class="cntnt"><table cellspacing="0"><colgroup width="25%"></colgroup><colgroup span="5" width="15%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Antibiotic agent</td> <td class="subtitle1">Antibiotic concentration</td> <td class="subtitle1">Heparin concentration</td> <td class="subtitle1">Maximum dwell time (duration of stability)*</td> <td class="subtitle1">References</td> </tr> <tr> <td class="divider_bottom" rowspan="10">Antibiotic agents with activity against gram-positive organisms</td> <td rowspan="3">Vancomycin</td> <td>2.5 mg/mL<sup>¶</sup></td> <td>2500 units/mL</td> <td>72 hours</td> <td>Krishnasami<sup>[1]</sup></td> </tr> <tr> <td>5 mg/mL<sup>Δ</sup></td> <td>5000 units/mL</td> <td>72 hours</td> <td>Luther<sup>[2]</sup></td> </tr> <tr> <td>5 mg/mL</td> <td>none</td> <td>72 hours</td> <td>Luther<sup>[2]</sup></td> </tr> <tr> <td rowspan="3">Cefazolin</td> <td>5 mg/mL<sup>◊</sup></td> <td>2500 units/mL</td> <td>72 hours</td> <td>Krishnasami<sup>[1]</sup></td> </tr> <tr> <td>5 mg/mL<sup>§</sup></td> <td>none</td> <td>48 hours</td> <td>Vercaigne<sup>[3]</sup></td> </tr> <tr> <td>10 mg/mL</td> <td>5000 units/mL</td> <td>72 hours</td> <td>Vercaigne<sup>[3]</sup></td> </tr> <tr> <td rowspan="2">Daptomycin</td> <td>5 mg/mL<sup>¥</sup></td> <td>5000 units/mL</td> <td>72 hours</td> <td>LaPlante<sup>[4]</sup></td> </tr> <tr> <td>5 mg/mL</td> <td>none</td> <td>72 hours</td> <td>LaPlante<sup>[4]</sup></td> </tr> <tr> <td>Nafcillin</td> <td>100 mg/mL</td> <td>none</td> <td>12 hours</td> <td>Nafcillin<sup>[5]</sup></td> </tr> <tr class="divider_bottom"> <td>Ampicillin</td> <td>10 mg/mL<sup>‡</sup></td> <td>none</td> <td>8 hours</td> <td>Ampicillin<sup>[6]</sup></td> </tr> <tr> <td rowspan="8">Antibiotic agents with activity against gram-negative organisms</td> <td rowspan="3">Gentamicin</td> <td>1 mg/mL<sup>†</sup></td> <td>2500 units/mL</td> <td>72 hours</td> <td>Krishnasami<sup>[1]</sup></td> </tr> <tr> <td>5 mg/mL**</td> <td>5000 units/mL</td> <td>72 hours</td> <td>Vercaigne<sup>[3]</sup></td> </tr> <tr> <td>5 mg/mL</td> <td>none</td> <td>72 hours</td> <td>Vercaigne<sup>[3]</sup></td> </tr> <tr> <td rowspan="2">Ceftazidime</td> <td>10 mg/mL<sup>¶¶</sup></td> <td>5000 units/mL</td> <td>48 hours</td> <td>Vercaigne<sup>[3]</sup></td> </tr> <tr> <td>1 to 10 mg/mL</td> <td>none</td> <td>48 hours</td> <td>Lee<sup>[7]</sup></td> </tr> <tr> <td>Cefepime</td> <td>1 to 10 mg/mL</td> <td>none</td> <td>48 hours</td> <td>Lee<sup>[7]</sup></td> </tr> <tr> <td>Ciprofloxacin</td> <td>1 to 5 mg/mL</td> <td>none</td> <td>48 hours</td> <td>Lee<sup>[7]</sup>, Lee<sup>[8]</sup></td> </tr> <tr> <td>Ceftriaxone</td> <td>100 mg/mL</td> <td>none</td> <td>48 hours</td> <td>Ceftriaxone<sup>[9]</sup></td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>Antibiotic lock solutions for the treatment of CRBSIs in the setting of catheter salvage should be used in conjunction with systemic antibiotic therapy. Refer to the UpToDate topics on treatment of CRBSI for further discussion. Refer to the UpToDate topic on hemodialysis catheter infections for discussion of approach to ALT in this setting.</li>
<li>The choice of antibiotic for ALT should be guided by the antimicrobial susceptibility of the infecting organism. There is no standard antibiotic or dosing regimen for use in ALT; thus far, there have been no rigorous studies comparing antibiotic lock solutions.</li>
<li>The solutions in the table are standardized to a 2 mL volume. If larger volumes are needed to fill the catheter lumen, the quantities should be adjusted accordingly.</li>
<li>Heparin is commonly used in ALT solutions to help maintain catheter patency; however, there are no comparative clinical studies demonstrating that ALT solutions containing heparin are more effective than solutions without heparin. Lock solutions with chemical compatibility between heparin and antimicrobial agents are summarized above; use of antibiotic lock solutions without heparin is also acceptable.</li>
<li>Ideally, ALT should be instilled at least once daily. The optimal dwell time is uncertain; dwell times may range from hours to days, depending on stability of the lock solution and the amount of time available when the catheter is not in use. Some studies support a minimum dwell time of 8 to 12 hours. Antibiotic concentrations may fall to subtherapeutic levels in the distal lumen of the catheter when dwell times exceed 48 to 72 hours.</li>
<li>If the line must be accessed for alternate use during the dwell time, the lock solution should be removed and later replaced with fresh solution.</li>
</ul></div><div class="graphic_footnotes">ALT: antibiotic lock therapy.<br/>* While antibiotics may remain stable in lock solutions based on their physical and chemical stability, in general, we favor limiting the dwell time to 24 to 48 hours, since antibiotic concentrations in the catheter can fall to subtherapeutic levels over time.<br/>¶ Vancomycin-heparin solution prepared by mixing vancomycin (0.5 mL of 10 mg/mL solution diluted in normal saline) plus heparin (0.5 mL of 10,000 units per mL solution) with 1 mL of normal saline for a final concentration of vancomycin 2.5 mg/mL and heparin 2500 units/mL in a 2 mL solution.<br/>Δ Vancomycin-heparin solution prepared by mixing vancomycin (1 mL of 10 mg/mL solution diluted in normal saline) plus heparin (1 mL of 10,000 units per mL solution) for a final concentration of vancomycin 5 mg/mL and heparin 5000 units/mL in a 2 mL solution.<br/>◊ Cefazolin-heparin solution prepared by mixing cefazolin (1 mL of 10 mg/mL solution diluted in normal saline) plus heparin (0.5 mL of 10,000 units per mL solution) with 0.5 mL of normal saline for a final concentration of cefazolin 5 mg/mL and heparin 2500 units/mL in a 2 mL solution.<br/>§ Cefazolin-heparin solution prepared by mixing cefazolin (1 mL of 20 mg/mL solution diluted in normal saline) plus heparin (1 mL of 10,000 units per mL solution) for a final concentration of cefazolin 10 mg/mL and heparin 5000 units/mL in a 2 mL solution.<br/>¥ Daptomycin-heparin solution prepared by mixing daptomycin (1 mL of 10 mg/mL solution diluted in lactated Ringer's) plus heparin (1 mL of 10,000 units per mL solution) for a final concentration of daptomycin 5 mg/mL and heparin 5000 units/mL in a 2 mL solution.<br/>‡ Ampicillin should be diluted with normal saline, lactated ringers, or sterile water for injection to achieve 8-hour stability; the stability of ampicillin is limited if diluted with 5% dextrose in water.<br/>† Gentamicin-heparin solution prepared by mixing gentamicin (0.5 mL of 4 mg/mL solution diluted in normal saline) plus heparin (0.5 mL of 10,000 units per mL solution) plus 1 mL of normal saline solution for a final concentration of gentamicin 1 mg/mL and heparin 2500 units/mL in a 2 mL solution.<br/>** Gentamicin-heparin solution prepared by mixing gentamicin (1 mL of 10 mg/mL solution diluted in normal saline) plus heparin (1 mL of 10,000 units per mL solution) for a final concentration of gentamicin 5 mg/mL and heparin 5000 units/mL in a 2 mL solution.<br/>¶¶ Ceftazidime-heparin solution prepared by mixing ceftazidime (1 mL of 20 mg/mL solution diluted in normal saline) plus heparin (1 mL of 10,000 units per mL solution) for a final concentration of ceftazidime 10 mg/mL and heparin 5000 units/mL in a 2 mL solution.</div><div class="graphic_reference">References:

	<ol>
<li>Krishnasami Z, Carlton D, Bimbo L, et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney International 2002; 61:1136.</li>
<li>Luther MK, Mermel LA, LaPlante KL. Comparison of linezolid and vancomycin lock solutions with and without heparin against biofilm-producing bacteria. Am J Health-Syst Pharm 2017; 74;e193.</li>
<li>Vercaigne LM, Sitar DS, Penner SB, et al. Antibiotic-heparin lock: in vitro antibiotic stability combined with heparin in a central venous catheter. Pharmacotherapy 2000; 20:394.</li>
<li>LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant 2007; 22:2239.</li>
<li>Nafcillin [package insert]. Dayton, NJ: AuroMedics Pharma LLC; 2013.</li>
<li>Ampicillin [package insert]. New York, NY: Pfizer Inc; 2010.</li>
<li>Lee MY, Ko KS, Song JH, Peck KR. In vitro effectiveness of the antibiotic lock technique (ALT) for the treatment of catheter-related infections by <em>Pseudomonas aeruginosa</em> and <em>Klebsiella pneumoniae</em>. J Antimicrob Chemother 2007; 60:782.</li>
<li>Lee JY, Ko KS, Peck KR, et al. In vitro evaluation of the antibiotic lock technique (ALT) for the treatment of catheter-related infections caused by staphylococci. J Antimicrob Chemother 2006; 57:1110.</li>
<li>Ceftriaxone [package insert]. Lake Forest, IL: Hospira Worldwide Inc; 2015.</li>
</ol></div><div id="graphicVersion">Graphic 122410 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
